AG 2195

Drug Profile

AG 2195

Alternative Names: AG-2195

Latest Information Update: 14 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corixa Corporation
  • Class
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myasthenia gravis

Most Recent Events

  • 17 May 2005 No development reported - Preclinical for Myasthenia gravis in Europe (unspecified route)
  • 30 May 2003 Beaufour-Ipsen is now called Ipsen
  • 22 Jan 2002 Beaufour Ipsen has acquired a licence for worldwide development and marketing of AG 2195 from Corixa Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top